Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Dermatology indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Actinic keratosis and field change

Dermatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Overview

Recognise individual actinic keratoses and field cancerisation, identify possible invasive SCC, choose lesion- or field-directed treatment and support long-term ultraviolet protection and surveillance.

Examine by sight and touch across the whole field. Record thin versus thick keratosis, tenderness, induration, ulceration and lip or ear involvement and palpate regional nodes when invasion is suspected. Erythema may be subtle in darker skin; scale, surface friction and focal thickening remain detectable. Actinic keratosis is less common in deeply pigmented skin, but a suspicious lesion still requires equivalent urgency.

Choose between lesion-directed and field-directed care. Cryotherapy suits a small number of discrete lesions. Field therapy treats visible and subclinical dysplasia but produces a larger inflammatory burden. Shared decisions include treatment duration, work and caring commitments, ability to apply to a mapped area, expected pain, cosmetic outcomes, immune status and capacity for review.

Before prescribing 5-fluorouracil, mark the exact field, exclude invasive foci and explain that inflammation is expected but uncontrolled pain, infection, severe ulceration or systemic symptoms require contact. Review after healing, not at peak reaction alone. Persistent focal thickening after a technically adequate field course needs biopsy rather than repeating treatment indefinitely.

Key points

  • Actinic keratosis is a rough, sandpaper-like keratotic macule or papule on chronically ultraviolet-exposed skin and may be easier to feel than see.
  • Field change means multiple lesions plus background mottling, atrophy and telangiectasia across a sun-damaged anatomical area.
  • Biopsy a tender, indurated, rapidly enlarging, bleeding, ulcerated, thick or treatment-resistant lesion to exclude invasive SCC.
  • Observation with protection is reasonable for selected thin asymptomatic lesions in lower-risk patients when follow-up and safety-netting are reliable.
  • Cryotherapy is lesion directed; topical 5-fluorouracil, imiquimod, diclofenac, tirbanibulin or photodynamic therapy can address a field according to site and licence.
  • For 5-fluorouracil 5% cream, a common licensed field regimen is once or twice daily for three to four weeks, with site-specific specialist directions.
  • Explain the expected sequence of redness, soreness, erosion and healing before field treatment and supply a stop and contact plan.
  • Use shade, clothing, hats and broad-spectrum sunscreen while avoiding messages that imply past ultraviolet damage can be reversed completely.

Aetiology

01

Cumulative ultraviolet exposure

Repeated ultraviolet injury creates clonal atypical keratinocytes on chronically exposed scalp, face, ears, forearms and dorsal hands.

02

Phenotypic and age risk

Lighter skin, bald scalp, older age and outdoor work increase cumulative damage, while any skin tone can develop actinic neoplasia.

03

Immune suppression

Transplantation and other impaired immune surveillance increase lesion number, progression risk and coexistence of invasive SCC.

04

Field cancerisation

Clinically normal-appearing sun-damaged skin can contain multiple mutated clones, explaining new lesions after successful spot treatment.

Pathophysiology

  1. 1
    Partial-thickness dysplasia

    Atypical keratinocytes begin in basal epidermis and produce disordered maturation, hyperkeratosis and a rough adherent surface.

  2. 2
    Clonal field expansion

    Multiple independent or related dysplastic clones occupy a photodamaged area, only some of which are clinically visible.

  3. 3
    Inflammatory hyperkeratosis

    Variable keratin and inflammation create thin gritty macules through thick plaques and horns, with grade not reliably predicting invasion alone.

  4. 4
    Progression to SCC

    A minority acquire additional changes, breach basement membrane and become invasive SCC; no individual lesion’s future can be predicted perfectly.

Clinical features and red flags

Gritty thin keratosis

A poorly defined rough macule feels like fine sandpaper on scalp, face, ear or dorsal hand.

Thick hyperkeratotic lesion

Adherent scale or a horn increases diagnostic uncertainty and requires careful assessment of the indurated base.

Actinic field change

Multiple keratoses sit within mottled, wrinkled, telangiectatic and atrophic chronically sun-damaged skin.

Actinic cheilitis

Persistent roughness, blurring and scale of the lower-lip vermilion has higher-consequence SCC potential and needs specialist assessment.

Invasive warningRed flag

New pain, induration, rapid growth, ulceration, bleeding or treatment resistance requires urgent biopsy for SCC.

Red flags requiring action

  • Induration, tenderness, rapid growth, ulceration, bleeding, a thick cutaneous horn, lip involvement, treatment resistance or immune suppression raises invasive SCC concern and requires urgent diagnostic review.

Investigations

  1. 01
    Full field examinationFirst step
    Why
    Map lesion burden, background damage and any focus suspicious for invasion.
    Interpretation and limitations
    Count is less important than identifying a tender indurated outlier and high-risk host or site.
  2. 02
    Dermoscopy
    Why
    Support actinic keratosis diagnosis and identify atypical vascular, follicular or keratin features.
    Interpretation and limitations
    Dermoscopy cannot exclude invasion when palpation or evolution is concerning.
  3. 03
    Punch, shave or excision biopsy
    Why
    Assess a thick, tender, indurated, ulcerated or resistant lesion for SCC.
    Interpretation and limitations
    Sample deeply enough to assess basement membrane and dermis; superficial keratin alone is inadequate.
  4. 04
    Baseline treatment-field photograph
    Why
    Define application boundaries and compare clearance after healing.
    Interpretation and limitations
    Use consent, secure storage, scale and consistent lighting; the image does not replace palpation.

Differential diagnosis

01

Invasive SCC

Induration, pain, rapid growth, ulceration, bleeding or a thick recurrent horn requires biopsy rather than further field treatment.

02

Bowen disease

A larger persistent well-demarcated scaly plaque represents full-thickness in-situ SCC and may need biopsy and different treatment planning.

03

Seborrhoeic keratosis

A waxy stuck-on lesion with comedo-like openings favours benign keratosis, though irritated lesions can remain uncertain.

04

Inflammatory dermatitis

Itchy confluent scale with a product or eczematous distribution lacks discrete sandpaper keratoses but can coexist on damaged skin.

Management

01Few discrete lesionsTreat or observe individuallyFirst stepA small number of typical thin lesions has no invasive warning and host risk is low.+
  1. 1Discuss observation versus lesion-directed cryotherapy based on symptoms, site and preference.
  2. 2For cryotherapy, obtain consent for pain, blister, pigment change and scar and use anatomy-appropriate freeze technique.
  3. 3Review non-clearance or focal thickening and biopsy rather than repeatedly freezing an uncertain lesion.
02Field cancerisationTreat the mapped fieldMultiple keratoses and subclinical photodamage occupy a defined area without suspected invasive SCC.+
  1. 1Mark the field, photograph with consent and choose 5-fluorouracil or another licensed option according to site, immune status and patient capacity.
  2. 2

Complications

01

Invasive squamous-cell carcinoma

Progression produces a firm destructive tumour with metastatic potential, particularly in immune suppression or high-risk sites.

02

Field recurrence

New visible keratoses arise from the altered field even after complete treatment of every current lesion.

03

Treatment inflammation

5-fluorouracil, imiquimod and photodynamic therapy deliberately inflame dysplastic skin and can interrupt sleep, work and social activity.

04

Pigment and scar change

Cryotherapy and severe inflammatory reactions can produce lasting hypo- or hyperpigmentation and occasional scarring, especially after overtreatment.

Monitoring and follow-up

  • Review during field therapy if pain, erosion or uncertainty threatens adherence and distinguish expected inflammation from infection or excessive injury.
  • Assess clearance after the reaction heals, palpating for persistent induration and not relying on colour alone.
  • Biopsy a focal lesion that persists, thickens, bleeds or becomes tender after adequate treatment.
  • Continue whole-field and whole-skin surveillance according to immune state and previous keratinocyte cancer burden.
  • Reinforce ultraviolet protection and self-awareness without presenting sunscreen as a guarantee against future cancer.

Special situations

Fingers can diagnose

A thin actinic keratosis may be more obvious as roughness under a fingertip than as colour change.

Field treatment reveals damage

Previously invisible dysplastic foci often inflame during 5-fluorouracil, illustrating subclinical field cancerisation.

A horn is not a grade

Thick keratin does not reliably distinguish in-situ from invasive disease; the base determines urgency.

Reaction and cure differ

Severe redness does not prove complete clearance, and a modest reaction does not automatically prove failure.

Common pitfalls

  1. 01

    Starting field cream over an indurated tender focus without excluding invasive SCC.

  2. 02

    Failing to mark the treatment boundary and allowing accidental eye or lip exposure.

  3. 03

    Interpreting expected 5-fluorouracil inflammation as allergy without assessing severity.

  4. 04

    Repeating cryotherapy on a resistant thick lesion instead of obtaining histology.

  5. 05

    Treating visible spots only while ignoring a heavily damaged surrounding field and future surveillance.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
DermatologyOriginal SBA

Tender thick field outlier

A patient with many thin scalp actinic keratoses has one rapidly thickening tender indurated lesion. What is the best next step?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Dermatology topics →
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Association of Dermatologists actinic keratosesRecognition, SCC warnings, treatment and prevention.
  • Efudix 5% cream SmPCFluorouracil field regimen, reactions and contraindications.
  • NICE NG12 suspected cutaneous SCC referralUrgent escalation of suspected invasive SCC.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Give exact application, expected inflammation, skin-care, infection and stop instructions and plan activity around the reaction.
  • 3Review after epithelial healing for field response and biopsy any persistent indurated or hyperkeratotic focus.
    • 03Possible invasive diseaseBiopsy before field treatmentPain, induration, ulceration, rapid growth, horn, lip involvement or treatment resistance is present.+
    1. 1Stop empirical destructive or field therapy and document size, depth impression, symptoms, immune state and nodes.
    2. 2Arrange urgent specialist biopsy with sufficient depth to assess invasion.
    3. 3DefinitiveRoute confirmed SCC through the skin-cancer multidisciplinary pathway and reassess the surrounding field after definitive treatment.
    Key medicines and prescribing safety1 treatment · regimens, roles and cautions+
    A licensed field treatment for actinic keratoses that targets visible and subclinical atypical keratinocytes.

    Fluorouracil 5% cream

    Apply a thin layer once or twice daily to the precisely defined actinic field for three to four weeks, or as directed for the anatomical site.

    Avoid pregnancy, eyes and mucosa; review severe inflammation, infection and dihydropyrimidine dehydrogenase deficiency risk, wash hands and follow site-specific specialist instructions.